Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aegon N.V. M&A Activity 2019

Jul 29, 2019

3803_rns_2019-07-29_ce462dc8-5d0b-4477-a615-7b21cbe98bb3.html

M&A Activity

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

The Vanguard Group, Inc. (IRSH)

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

29-Jul-2019 / 13:40 GMT/BST

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.


Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.  KEY INFORMATION

Name of person dealing (Note 1) The Vanguard Group, Inc.
Company dealt in Allergan plc
Class of relevant security to which the dealings being disclosed relate (Note 2) US$0.0001 Ordinary Shares
Date of dealing 26 July 2019

2.  INTERESTS AND SHORT POSITIONS

(a)  Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long Short
Numbers (%) Numbers (%)
(1) Relevant securities 24,247,588 7.40%
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total 24,247,588 7.40%

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
Numbers (%) Numbers (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.  Dealings (Note 4)

(a)  Purchases and sales

Purchase/sale Number of relevant securities Price per unit (Note 5)
Sale 621 160.05 USD
Purchase 4,001 160.05 USD

(b)  Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit

(Note 5)
Not Applicable

(c)  Options transactions in respect of existing relevant securities

(i)  Writing, selling, purchasing or varying

Product name,

e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
Not Applicable

(ii)  Exercising

Product name,

e.g. call option
Number of securities Exercise price per unit (Note 5)
Not Applicable

(e)  Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
Details Price per unit

(if applicable) (Note 5)
Not Applicable

Ap21

2.  OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                           NO

Date of disclosure 29 July 2019
Contact name Shawn Acker
Telephone number 001-610-669-8989
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Category Code: RET - Allergan plc
TIDM: IRSH
LEI Code: 5493002789CX3L0CJP65
Sequence No.: 14964
EQS News ID: 848195
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=848195&application_name=news&site_id=morningstar